To explore suitable imaging probes for early and specific detection of pancreatic cancer, we demonstrated that Î☖Î☤ integrin is a good target and employed single-photon emission computed tomography (SPECT) or near-infrared (NIR) imaging for immunotargeting. Sudo, Hitomi Sugyo, Aya Furukawa, Takako Ukai, Yoshinori Kurosawa, Yoshikazu Saga, Tsuneo Immunotargeting of Integrin Î☖Î☤ for Single-Photon Emission Computed Tomography and Near-Infrared Fluorescence Imaging in a Pancreatic Cancer Model New antibody analogues and pretargeting strategies have also considerably improved the performances of tumor immunotargeting and completely renewed the interest in these approaches for imaging and therapy by providing theranostics, companion diagnostics and news tools to make personalized medicine a reality. At the same time, PET imaging, with short-lived radionuclides, such as gallium-68, fluorine-18 or copper-64, or long half-life ones, particularly iodine-124 and zirconium-89 now offers new perspectives in immuno-specific phenotype tumor imaging. However, alternative radionuclides, with more appropriate physical properties, such as lutetium-177 or copper-67, as well as alpha-emitting radionuclides, including astatine-211, bismuth-213, actinium-225, and others are currently reviving hopes in cancer treatments, both in hematological diseases and solid tumors. While radiolabeled antibodies have been considered for many years in this context, only a few have reached the level of routine clinical use. This paper reviews some aspects and recent developments in the use of antibodies to target radionuclides for tumor imaging and therapy. Kraeber-BodÃ©rÃ©, FranÃ§oise Rousseau, Caroline Bodet-Milin, Caroline Mathieu, CÃ©dric GuÃ©rard, FranÃ§ois Frampas, Eric Carlier, Thomas Chouin, Nicolas Haddad, Ferid Chatal, Jean-FranÃ§ois Faivre-Chauvet, Alain ChÃ©rel, Michel Barbet, Jacques Tumor Immunotargeting Using Innovative Radionuclides

Quickmap 3d smi manual